Search Medical Condition
Please enter condition
Please choose location from dropdown

Familial Hypercholesterolemia Clinical Trials

A listing of Familial Hypercholesterolemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (33) clinical trials

The purpose of this registry is to collect and maintain clinical information about patients that have been diagnosed with Familial Hypercholesterolemia (FH). The information will be used to look at current treatment, events, and outcomes of these patients. This will help further the understanding of the disease and improve care, ...

Phase N/A

Greek Registry - Familial Hypercholesterolaemia

In contrast, timely recognition and effective treatment of FH can result in a significant improvement in clinical outcomes. The problem is that that majority of individuals with FH are unaware of their disease, particularly that the disease remains silent for many years. In most countries around the world <5% of ...

Phase N/A

a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia

Objective 1.1.Primary Objective To estimate the prevalence of clinical diagnosed familial hypercholesterolemia, as well as the clinical characteristics and current treatment, with applying China recent issued FH screening protocol in pilot outpatient department of China. 1.2.Secondary Objective To describe parameters related to clinical management of diagnosed FH, including patient demographics ...

Phase N/A

Safety Tolerability Pharmacokinetics and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS ANGPTL3-LRx (ISIS 703802) given to healthy volunteer subjects with elevated triglycerides and subjects with familial hypercholesterolemia.

Phase

Developing and Implementing Familial Hypercholesterolemia Registry

Familial hypercholesterolemia (FH) is a genetic disorder define as high cholesterol levels, particularly very high levels of low-density lipoprotein (LDL), in the blood and early cardiovascular disease and premature death. FH is an autosomal dominant disease with a prevalence 1:500 (new study in Netherlands demonstrated 1:244) in population more frequent ...

Phase N/A

Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada

Familial hypercholesterolemia (FH) is a genetic lipoprotein disorder characterized by elevations in low-density lipoprotein cholesterol (LDL-C) >95th percentile for age and gender. Affected individuals may show clinical manifestations (xanthomas, xanthelasmas and premature arcus corneus) although these manifestations are seen less frequently with early diagnosis and treatment. Untreated, FH will lead ...

Phase N/A

A Registration Study for Familial Hypercholesterolemia in Taiwan

Familial hypercholesterolemia (FH) is an inherited disorder of lipoprotein metabolism, transmitted in an autosomal dominant manner and clinically characterized by elevated levels of total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol, the presence of tendon xanthomas, and premature atherosclerosis.The genetic basis of FH is a large array of point mutations ...

Phase N/A

Familial Hypercholesterolemia Amongst Patients With Acute Coronary Syndrome

Familial hypercholesterolemia (FH) is a genetic disorder, defines as high cholesterol levels, particularly very high levels of low-density lipoprotein (LDL), in the blood and early cardiovascular events and premature death. FH is an autosomal dominant disease with a prevalence of 1:500 (new study in Netherlands demonstrated 1:244) in population more ...

Phase N/A

Aortic Stenosis in Subjects With Heterozygous Familial Hypercholesterolemia on Prolonged Treatment With Statins

The study includes a single clinical visit with collection of clinical data, blood extraction and the performance of a transthoracic echocardiogram. This visit may be made on different days, but always within 30 days of signing the informed consent.

Phase N/A